Marcus Irsfeld

Artract Medical, Inc. is a medical device company based in New York, NY. The company has developed a passive hemodynamic assist device called the Artract System, which is implanted percutaneously to treat heart failure with preserved ejection fraction (HFPEF). HFPEF is a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood. The Artract System reduces shortness of breath, improves exercise tolerance, and reduces the need for daily medication and frequent hospital stays. The company was founded by Marcus Irsfeld and Wolfgang Gœtz.

Artract Medical, Inc. is a medical device company based in New York, NY. The company has developed a passive hemodynamic assist device called the Artract System, which is implanted percutaneously to treat heart failure with preserved ejection fraction (HFPEF). HFPEF is a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood. The Artract System reduces shortness of breath, improves exercise tolerance, and reduces the need for daily medication and frequent hospital stays. The company was founded by Marcus Irsfeld and Wolfgang Gœtz.

Artract Medical, Inc. is a medical device company based in New York, NY. The company has developed a passive hemodynamic assist device called the Artract System, which is implanted percutaneously to treat heart failure with preserved ejection fraction (HFPEF). HFPEF is a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood. The Artract System reduces shortness of breath, improves exercise tolerance, and reduces the need for daily medication and frequent hospital stays. The company was founded by Marcus Irsfeld and Wolfgang Gœtz.